Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Cardiome Pharma's board authorizes buyback of shares

Cardiome Pharma's board authorizes buyback of shares

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

National Science Foundation funds CMU for developing revolutionary computational tools

National Science Foundation funds CMU for developing revolutionary computational tools

Aryx Therapeutics reports Q2 2009 financials

Aryx Therapeutics reports Q2 2009 financials

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Decode Genetics announces Q2 2009 financials

Decode Genetics announces Q2 2009 financials

Multaq approved for atrial fibrillation by FDA

Multaq approved for atrial fibrillation by FDA

Atrial fibrillation linked to increased hospitalization in heart failure patients

Atrial fibrillation linked to increased hospitalization in heart failure patients

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

Big disparities in the treatment of arrhythmias across Europe

Big disparities in the treatment of arrhythmias across Europe

A link found between atrial fibrillation and Alzheimer's disease

A link found between atrial fibrillation and Alzheimer's disease

Catheter ablation effective for atrial fibrillation

Catheter ablation effective for atrial fibrillation

Atrial fibrillation more difficult to identify in blacks than whites; might explain lower prevalence, study finds

Atrial fibrillation more difficult to identify in blacks than whites; might explain lower prevalence, study finds

Prevalence and physiological predictors of sleep apnea in patients with heart failure

Prevalence and physiological predictors of sleep apnea in patients with heart failure

Researchers identify atrial fibrillation as a stroke predictor in black patients

Researchers identify atrial fibrillation as a stroke predictor in black patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.